menu
    • menu
    [{"orgOrder":0,"company":"Mabion SA","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"POLAND","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"COVID-19 Vaccine, Adjuvanted","moa":"||SARS-CoV-2 S||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mabion SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabion SA \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"Mabion SA \/ Novavax"},{"orgOrder":0,"company":"IBSS BIOMED","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"POLAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tetanus-Diphtheria Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IBSS BIOMED","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IBSS BIOMED \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"IBSS BIOMED \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            IBSS BIOMED

                            Poland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            IBSS BIOMED

                            Poland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetanus-Diphtheria Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immunogenicity and Safety of Vaccine Against Tetanus and Diphtheria.

                            Details : Clodivac (Tetanus-Diphtheria Vaccine) is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diphtheria.

                            Product Name : Clodivac

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            July 29, 2022

                            Lead Product(s) : Tetanus-Diphtheria Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mabion SA

                            Poland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Mabion SA

                            Poland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NVX-COV2373,COVID-19 Vaccine, Adjuvanted,Matrix-m1

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Novavax

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Mabion Announces Agreement with Novavax for Large-Scale Vaccine Manufacturing Feasibility Assessment

                            Details : Upon Mabion’s successful production of the technical batches, the parties may enter into a broader contract for the production of antigen for NVX-CoV2373 for commercial use, should it be approved by regulatory agencies.

                            Product Name : Nuvaxovid

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 03, 2021

                            Lead Product(s) : NVX-COV2373,COVID-19 Vaccine, Adjuvanted,Matrix-m1

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Novavax

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth